Friday 6 November 2026 Export MIRM’s income statement to Excel — free account

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.

Revenue: +39.6%
EPS: −1,136.8%
Free cash flow: −114.2%
Total debt: +136.4%

Quarter to September 2026, against a year earlier

93.82 0.28 +0.30%

Follow MIRM

Alert me

Market cap: $6.1B
P/E: 0.0×
Fwd P/E: −5.6×
Dividend yield: —
F-score: 6/9
Altman Z: 4.42
Beneish M: −2.46
Dividend safety: n/a

Overview

Mirum Pharmaceuticals, Inc. (MIRM) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Mirum Pharmaceuticals, Inc. (MIRM) trades at a P/S ratio of 9.2×. Over the past ten years it has ranged from 0.0× (March 2022) to 26.9× (April 2022); the current reading is higher than 74% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MIRM/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Mirum Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MIRM/metrics/ps-ratio">Mirum Pharmaceuticals, Inc. (MIRM) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	7.6×	30.40%
FY2024	5.8×	(11.43%)
FY2023	6.6×	(22.21%)
FY2022	8.5×	—
FY2021	0.0×	—

Period	P/S ratio	Change
Sep 2026	8.4×	(30.44%)
Jun 2026	12.0×	25.77%
Mar 2026	9.5×	25.48%
Dec 2025	7.6×	(3.34%)
18 more quarters	Free account

Against its own ten years

Low 0.0× High 26.9×

Ten-year median 6.4×

Current reading's percentile 59

Company	P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare	n/m
IMVT Immunovant, Inc. compare	n/m
ORKA Oruka Therapeutics, Inc. compare	n/m
KOD Kodiak Sciences Inc. compare	n/m
PTCT PTC Therapeutics, Inc. compare	4.8×
IONS Ionis Pharmaceuticals, Inc. compare	7.4×
MIRM Mirum Pharmaceuticals, Inc.	9.2×
LGND Ligand Pharmaceuticals Incorporated compare	23.6×
CGON CG Oncology, Inc. compare	919×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Mirum Pharmaceuticals, Inc. (MIRM) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on MIRM

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on MIRM

Stockrow Weekly